Featured Story

Quest and LabCorp won't accept blood samples from suspected Ebola patients

Quest Diagnostics and LabCorp, two of the biggest laboratory diagnostics outfits around, will not accept any blood samples from patients suspected of having the Ebola virus.

Virginia Tech finds possible biomarker for rare immunodeficiency condition

Virginia Tech researchers believe they've found a possible biomarker to help detect a rare genetic disease known as severe combined immunodeficiency, or SCID, which leaves patients needing to avoid all human contact and breathe filtered air in order to survive.

Gene sequencing helps Northwestern team diagnose one cause of epilepsy

Researchers at Northwestern University's Feinberg School of Medicine used a form of gene sequencing to identify mutations that appear to be behind a type of epilepsy disorder.

Biocept, Rosetta Genomics want to beef up Dx and biomarker-detection power

Biocept forged a partnership deal with a competitor that aims to build an enhanced molecular diagnostics test for circulating tumor cells in the blood. Success could breed a more precise test that aids patient diagnoses and drug development in equal measure.

British startup finishes quick and easy Ebola test

As anxiety levels over ebolavirus increase, a British startup is stepping up to the plate with what it claims is a quick and easy diagnostic test. If successful, the company's advance could help clinicians intervene with treatment far earlier than possible now, boosting a patient's survival chances.


From Our Sister Sites


Earlier this year, Cytokinetics tanked as its lead prospect, a treatment for amyotrophic lateral sclerosis (ALS), missed its primary endpoint and a slew of secondary goals in a mid-stage trial. But the drug did come through on one measure of lung function, and, upon analysis of the results, the biotech believes that could be its ticket to FDA approval.


A panel of FDA advisers voted unanimously in favor of approving Novartis' new anti-inflammatory treatment, an expected positive outcome for the company as it races to be first in line among what promises to be a crowded field.